脊髓损伤住院病人的医疗和非医疗费用调查分析

目的调查脊髓损伤住院病人的医疗和非医疗费用的支付情况及其主要影响因素.对损伤后疾病负担做出基本估计,为残疾预防,促进与维护健康提供有价值的参考依据.方法以1998-2001年脊髓损伤康复科出院患者的原始资料为依据,自行设计费用调查问卷.资料应用SPSS完成.结果111例脊髓损伤住院病人医疗费用占总费用占58.03%,非医疗费用占41.97%.康复训练费用仅占医疗费用的12.86%.脊髓不完全性损伤费用多,康复治疗效果明显,患者的期望值高,因此住院时间较长.费用来源于公费、肇事责任方的患者平均住院日及费用无明显差异,自费患者住院天数、医疗费用明显减少.在脊髓损伤后非医疗费用中,陪护费占34.26%.结论遏止交通事故,工业伤害,减轻社会的总体负担;要逐步降低康复医院的药品费用的比重,提高康复训练中技术服务价值:应将脊髓损伤纳入重大疾病预防控制工作.     

强化躯干核心肌群对脑卒中患者躯干控制平衡步行及日常生活能力的康复效果

目的探讨躯干核心肌群训练的强度对脑卒中患者躯干控制、平衡步行及日常生活能力的康复效果。方法选择2017年4月至2018年3月在华中科技大学同济医学院附属协和医院康复医学科住院治疗的90例脑卒中偏瘫患者为研究对象,按照随机数字表法将患者分为A、B、C组,每组各30例,3组患者均在常规治疗基础上联合不同强度的躯干核心肌群训练,其中A组每天训练1次,B组每天训练2次,C组每天训练3次,每次训练30 min,每周5天,共训练3个月。3组患者治疗1个月、2个月和3个月时采用躯干控制能力测试(TCT)、Berg平衡量表(BBS)评价躯干控制能力,采用步行功能评级(FAC)评定平衡步行功能、采用日常生活能力(MBI)评定日常生活能力。比较3组患者上述评分差异。结果治疗前3组患者躯干控制能力、平衡步行功能和生活能力评分比较差异无统计学意义(P> 0. 05),3组患者治疗1个月、2个月、3个月后躯干控制、平衡步行和日常生活能力评分均逐渐提高,差异均有统计学意义(P均<0. 05);且在1～3个月期间躯干控制和平衡能力评分C组高于B组,B组高于A组,差异均有统计学意义(P均<0. 05),但3个月时差异无统计学意义(P> 0. 05)。3组患者步行和日常生活能力在1个月期间组间差异无统计学意义(P> 0. 05),但1个月后C组较B组,B组较A组均有统计学意义(P均<0. 05)。结论强化躯干核心肌力量可以显著提高患者躯干控制、平衡步行和日常生活能力,缩短康复时间。     

论“医疗保健价格指数”与“看病贵”

无论是居民感受还是学者研究，多年来我国持续存在看病贵这一社会热点问题。但现行的医疗保健价格指数披露出相反的结论。本文提出用门诊病人次均医药费、出院病人人均医药费指标，来计算医疗保健类价格指数，以更科学、准确地反映患者医药费用负担水平及其变动趋势。     

利用1＋3模式改进医院成本核算

针对全成本核算过程中收入数据统计存在的问题，运用1＋3质量管理模式进行持续改进，通过分析查找根本原因，完善服务流程，建立相关制度，提高执行科室归并的准确性，以此更加准确反映各科室的收入情况，保证全成本核算的质量。     

The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance

Abstract

Objectives: Potential opportunities and challenges of predictive genetic risk classification of healthy persons are currently discussed. However, the budgetary impact of rising demand is uncertain. This project aims to evaluate budgetary consequences of predictive genetic risk classification for statutory health insurance in Germany.

Methods: A Markov model was developed in the form of a cohort simulation. It analyzes a population of female relatives of hereditary breast cancer patients. Mutation carriers are offered intensified screening, women with a BRCA1 or BRCA2 mutation can decide on prophylactic mastectomy and/or ovarectomy. The model considers the following scenarios: (a) steady demand for predictive genetic testing, and (b) rising demand. Most input parameters are based on data of the German Consortium for Hereditary Breast and Ovarian Cancer. The model contains 49 health states, starts in 2015, and runs for 10 years. Prices were evaluated from the perspective of statutory health insurance.

Results: Steady demand leads to an expenditure of €49.8 million during the 10-year period. Rising demands lead to additional expenses of €125.5 million. The model reveals the genetic analysis to be the main cost driver while cost savings in treatment costs of breast and ovarian cancer are indicated.

Conclusions: The results contribute to close the knowledge gap concerning the budgetary consequences due to genetic risk classification. A rising demand leads to additional costs especially due to costs for genetic analysis. The model indicates budget shifts with cost savings due to breast and ovarian cancer treatment in the scenario of rising demands.     

Heavy metals in agricultural soils and crops and their health risks in Swat District,northern Pakistan

This study assessed the concentrations of heavy metals such as cadmium (Cd), chromium (Cr), copper (Cu), manganese (Mn), nickel (Ni) and zinc (Zn) in agricultural soils and crops (fruits, grains and vegetable) and their possible human health risk in Swat District, northern Pakistan. Cd concentration was found higher than the limit (0.05 mg/kg) set by world health organization in 95% fruit and 100% vegetable samples. Moreover, the concentrations of Cr, Cu, Mn, Ni and Zn in the soils were shown significant correlations with those in the crops. The metal transfer factor (MTF) was found highest for Cd followed by Cr > Ni > Zn > Cu > Mn, while the health risk assessment revealed that there was no health risk for most of the heavy metals except Cd, which showed a high level of health risk index (HRI ⩾ 10E-1) that would pose a potential health risk to the consumers.     

Modifiable Factors to Decrease the Cost of Robotic-Assisted Procedures

In 2000, the US Food and Drug Administration approved the da Vinci Surgical System® for use in the United States. Since that time, the number of surgical robotic systems throughout the United States has continued to grow. The costs for using the system include the initial purchase ($1 million to $2.3 million) plus annual maintenance fees ($100,000 to $150,000) and the cost of limited-use or disposable instruments. Increasing the number of procedures that are performed using the robotic system can decrease the per-procedure costs. Two modifiable factors that contribute to increasing the annual caseload are increasing the number of surgeons capable of using the system and having a properly educated perioperative nursing team. An educated surgical team decreases turnover time, facilitates proper flow of each surgical procedure, and is able to actively and passively solve intraoperative problems.     

Exoskeleton plantarflexion assistance for elderly

Elderly are confronted with reduced physical capabilities and increased metabolic energy cost of walking. Exoskeletons that assist walking have the potential to restore walking capacity by reducing the metabolic cost of walking. However, it is unclear if current exoskeletons can reduce energy cost in elderly. Our goal was to study the effect of an exoskeleton that assists plantarflexion during push-off on the metabolic energy cost of walking in physically active and healthy elderly. Seven elderly (age 69.3 ± 3.5 y) walked on treadmill (1.11 m s²) with normal shoes and with the exoskeleton both powered (with assistance) and powered-off (without assistance). After 20 min of habituation on a prior day and 5 min on the test day, subjects were able to walk with the exoskeleton and assistance of the exoskeleton resulted in a reduction in metabolic cost of 12% versus walking with the exoskeleton powered-off. Walking with the exoskeleton was perceived less fatiguing for the muscles compared to normal walking. Assistance resulted in a statistically nonsignificant reduction in metabolic cost of 4% versus walking with normal shoes, likely due to the penalty of wearing the exoskeleton powered-off. Also, exoskeleton mechanical power was relatively low compared to previously identified optimal assistance magnitude in young adults. Future exoskeleton research should focus on further optimizing exoskeleton assistance for specific populations and on considerate integration of exoskeletons in rehabilitation or in daily life. As such, exoskeletons should allow people to walk longer or faster than without assistance and could result in an increase in physical activity and resulting health benefits.     

The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transuretheral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction

BackgroundIn 2008, a UK assessment of technologies for benign prostatic obstruction concluded negatively about photoselective vaporization of the prostate (PVP), and the 2010 National Institute for Health and Care Excellence guidance caused several UK institutions to abandon PVP.ObjectiveTo reassess the costs and effects of PVP versus transurethral resection of the prostate (TURP) on the basis of most recent data.MethodsThe same model was used as in 2008. Transition probabilities were estimated using a Bayesian approach updating the 2008 estimates with data from two meta-analyses and data from GOLIATH, the latest and largest trial comparing PVP with TURP. Utility estimates were from the 2008 assessment, and estimates of resource utilization and costs were updated. Effectiveness was measured in quality-adjusted life-years gained, and costs are in UK pounds. The balance between costs and effects was addressed by multivariate sensitivity analysis.ResultsIf the 2010 National Institute for Health and Care Excellence analysis would have updated the cost-effectiveness analysis with figures from its own meta-analysis, it would have estimated the change in quality-adjusted life-years at −0.01 (95% confidence interval [CI] −0.05 to 0.01) instead of at −0.11 (95% CI −0.31 to −0.01) as in the 2008 analysis. The GOLIATH estimate of −0.01 (95% CI −0.07 to 0.02) strengthens the conclusion of near equivalence. Estimates of additional costs vary from £491 (£21−£1286) in 2008 to £111 (−£315 to £595) for 2010 and to £109 (−£204 to £504) for GOLIATH. PVP becomes cost saving if more than 32% can be carried out as a day case in the United Kingdom.ConclusionsThe available evidence indicates that PVP can be a cost-effective alternative for TURP in a potentially broad group of patients.